Captrust Financial Advisors Replimune Group, Inc. Transaction History

Captrust Financial Advisors

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$6.75 - $16.18 $200,218 - $479,931	-29,662 Reduced 69.2%	13,204 $111,000
Q3 2023 Nov 14, 2023	SELL	$15.96 - $22.18 $24,115 - $33,513	-1,511 Reduced 3.4%	42,866 $733,000
Q2 2023 Aug 14, 2023	BUY	$15.65 - $24.1 $694,500 - $1.07 Million	44,377 New	44,377 $1.03 Million

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $693M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.